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Patients with Chronic Mucocutaneous Candidiasis
Exhibit Reduced Production of Th17-Associated
Cytokines IL-17 and IL-22
Kilian Eyerich1,3, Stefanie Foerster1,3, Stephanie Rombold2, Hans-Peter Seidl2, Heidrun Behrendt1,
Heidelore Hofmann2, Johannes Ring2 and Claudia Traidl-Hoffmann1
Chronic mucocutaneous candidiasis (CMC) constitutes a selective inability to clear infection with the yeast
Candida, resulting in persistent debilitating inflammation of skin, nails, and mucous membranes. The underlying
defect is unknown. Only recently, IL-17-producing T cells have been reported to be involved in clearing Candida
infections. In order to characterize Tcellular immune response to Candida, we analyzed T-cell cytokine secretion to
Candida antigen and mitogenic stimuli in CMC patients, immunocompetent patients suffering from acute Candida
infection, and healthy volunteers. Peripheral blood mononuclear cells (PBMCs) from CMC patients produced
significantly lower amounts of IL-17 and IL-22 mRNA and protein when stimulated with Candida albicans or
mitogen in vitro compared with that in matched healthy individuals. Additionally, PBMCs from immuno-
competent Candida-infected patients secreted more IL-17 and IL-22 than those of both CMC patients and healthy,
non-infected controls. Flow cytometry revealed a decreased number of CCR6þ IL-17-producing T cells in CMC
patients, whereas the amount of CCR6þ /CCR4þ cells was not altered. Levels of differentiating cytokines for
human Th17 cells, IL-1b and IL-6, tended to be higher in CMC patients. The inability to clear C. albicans in CMC
patients could be due to a defect in the immune response of IL-17-producing T cells.
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INTRODUCTION
Chronic mucocutaneous candidiasis (CMC) is a rare, com-
plex, and heterogeneous group of syndromes characterized
by persistent or recurrent infections of skin, nails, and
mucosal tissues with the ubiquitous, opportunistic yeast
Candida albicans (Kirkpatrick, 2001). The underlying defect
may be a primary immune defect, as it is the case in the
recently described subgroup ‘‘Autoimmune polyendocrino-
pathy candidiasis ectodermal dystrophy’’ (APECED) (Collins
et al., 2006), or in a form of dominant inherited CMC with
malfunction of the thyroid gland (Atkinson et al., 2001).
However, the link between these mutations and the immune
defect(s) remains unclear.
Even though a coordinated contribution of both innate and
adaptive immunity is required in order to mount an effective
host response against Candida, it seems that primarily a defect
of the adaptive immune system leads to enhanced Candida
infection. Patients lacking T cells due to a severe combined
immunodeficiency often undergo chronic mucocutaneous
candidiasis (IUIS scientific group, 1999). T-cell-knockout mice
suffer from severe systemic candidiasis (Ashman et al., 1999);
impaired T helper-1 (Th1) immune response leads to increased
susceptibility to severe Candida infections (Mencacci et al.,
2001), whereas reduction of IL-10 increases resistance against
these infections (Tavares et al., 2000). The recently described
T-cell subtype Th17, characterized by production of IL-17 and
expression of CCR6 (Harrington, 2006; Singh et al., 2008), has
been found, aside its involvement in autoimmune diseases
and immunosurveillance, to be involved in host defense
against Candida in mice and humans (Huang et al., 2004;
Acosta-Rodriguez et al., 2007b; Bettelli et al., 2007).
Concerning CMC, we, and others, reported a heteroge-
neous, but not generally diminished, proliferative capacity of
T cells from CMC patients (De Morales-Vasconcelos et al.,
2001; Eyerich et al., 2007). A more critical parameter in the
pathogenesis of CMC could be the cytokine secretion of
T-cell subtypes rather than proliferation: recently, T-cell
cytokine secretion has been the focus of numerous studies
(Kobrynski et al., 1996; Lilic et al., 2003; Van der Graaf et al.,
2003; Eyerich et al., 2007), describing an altered cytokine
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production with a reduced production of type-1 cytokines
such as IFN-g, IL-12, and IL-2, and increased secretion of
IL-10 or IL-4.
The aim of this study was to elucidate a possible role for
IL-17-producing T cells in the pathogenesis of CMC.
RESULTS
Candida- and PHA-stimulated PBMCs from CMC patients
transcribe and secrete less IL-17 and IL-22 compared with those
in healthy controls
PBMCs of two CMC patients and two age- and sex-matched
controls were stimulated with C. albicans. After 24 hours,
total mRNA was isolated, reverse transcribed, and used for
real-time PCR. In healthy (non-Candida infected) controls,
IL-17F and IL-22 were significantly induced after 24 hours
of stimulation with Candida or phytohemagglutinin (PHA),
whereas CMC patients failed to upregulate the expression of
these cytokines on mRNA level (Figure 1a), irrespective of the
stimulus. IL-17A was not upregulated in CMC patients and
healthy controls in the monitored time course (data not
shown).
The low transcription of IL-17 and IL-22 mRNA in CMC
patients was reflected by the scarce and significantly lower
secretion of IL-17 and IL-22 as compared with that in healthy
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Figure 1. PBMCs of CMC patients exhibit significantly reduced expression and release of IL-17 and IL-22 upon stimulation with Candida or PHA. Total mRNA
of PBMCs was isolated 24 hours after stimulation with C. albicans or PHA, reverse transcribed, and analyzed by real-time PCR for IL-17F and IL-22 transcription
(CMC patients, n¼ 2; IC, non-Candida-infected control, n¼ 2) (a). The culture supernatants of PBMCs stimulated for 72 hours with C. albicans, PHA or
anti-CD3/anti-CD28 were analyzed by ELISA for protein content of IL-17 and IL-22 (CMC patients, n¼ 4; IC, non-Candida-infected control, n¼ 9; IC,
Candida-infected control, n¼ 6) (b). CD4þ or CD8þ T cells were incubated with autologous monocytes and Candida for 72 hours, and supernatants were
analyzed for IL-17 and IL-22 by ELISA (CMC patients, n¼2; IC, non-Candida-infected control, n¼ 4) (c). Error bars indicate mean±SD (IC, immunocompetent
control; *Pp0.05; **Pp0.01; ***Pp0.001).
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controls as measured by ELISA after 72 hours of stimulation
with PHA or Candida (Figure 1b). Notably, IL-17 and IL-22
release were also reduced in CMC patients when PBMCs
were stimulated with anti-CD3/anti-CD28, pointing to a
defect in
the T-cell compartment rather than antigen-presentation
or absent antigen-presenting cell-derived signals. Further-
more, PBMCs from immunocompetent patients with acute
Candida infection exhibited not only significantly higher
release of IL-17 upon stimulation with Candida compared
with CMC patients, but also compared with healthy controls.
This underlines the importance of IL-17 in defense against
Candida.
Incubation of purified CD4þ and CD8þ T cells with
autologous monocytes as antigen-presenting cells and
Candida revealed that IL-17 and IL-22 are predominantly
derived from CD4þ T cells in healthy controls, and
conclusively, the disability of CMC patients to produce IL-
17 and IL-22 is mainly attributed to CD4þ T cells (Figure 1c).
CMC patients exhibit reduced total number of IL-17-producing
T cells, but normal amounts of CCR6þ /CCR4þ T cells
The surface phenotype of IL-17-producing T cells is charac-
terized by CCR4 and CCR6. Here we confirm these data
showing that the majority of IL-17-producing cells expressed
CCR6 (Figure 2a). In line with our data from ELISA, CMC
patients showed an evanescent number of IL-17-producing
(CCR6þ ) T cells after phorbol 12-myristate 13-acetate/
ionomycin stimulation. However, no significant differences
in the number of CCR4þ , CCR6þ and CCR4/CCR6 double
positive cells between CMC patients and healthy controls
were observed (Figure 2b).
PBMCs of CMC patients are able to secrete Th17-differentiating
and Th17-maintaining cytokines
IL-1b and IL-6 are important for differentiation of human
IL-17-producing T cells. We analyzed the expression of
IL-1b and IL-6 at the transcriptional level by real-time
PCR (Figure 3a). PBMCs of CMC patients stimulated with
C. albicans for 24 hours tended to show higher mRNA
expression of IL-1b and IL-6 compared those of with healthy
controls. Transcriptional upregulation of these genes in CMC
patients resulted in only slightly higher amounts of corre-
sponding protein measured by ELISA in culture supernatants
of Candida- or PHA-stimulated PBMCs after 72 hours
(Figure 3b). IL-23, a cytokine important for maintenance
of Th17 cells, was analyzed on mRNA level, revealing no
differences in expression between patients and controls (data
not shown).
DISCUSSION
Recent data suggest that the inability to clear C. albicans
in CMC patients is based upon a complex heterogeneity
of immune defect(s), probably characteristic for various
disease subgroups. In this study, we present four CMC
patients deficient in the production of Th17-associated
cytokines IL-17 and IL-22, whereas levels of the medi-
ators important for differentiation (IL-6 and IL-1b) and
maintenance (IL-23) of the Th17 lineage were enhanced or
not altered.
IL-17-producing T cells represent a recently described
T-cell subset characterized by production of IL-17 and
IL-22 (Liang et al., 2006; Bettelli et al., 2007). They are
proinflammatory linkers between myeloid and lymphoid host
defense that are able to help B cells, show low cytotoxicity,
and poor regulative susceptibility to T regulatory cells
(Annunziato et al., 2007).
First evidence for the importance of IL-17 in clearing
Candida infections has been provided in the mouse system:
IL-17A-receptor-knockout mice showed a dose-dependent,
substantially reduced survival in a murine model of systemic
candidiasis (Huang et al., 2004). Recent data revealed that
infection with C. albicans leads to induction of murine IL-17-
producing T cells (LeibundGut-Landmann et al., 2007).
Furthermore, the hyphal form of C. albicans triggers IL-17
production of freshly isolated human CD4þ T cells of
healthy donors in vitro (Acosta-Rodriguez et al., 2007b).
Our study affirms the importance of IL-17 producing-T
cells in clearing Candida infections, because PBMCs of
immunocompetent patients suffering from Candida infection
showed significantly higher secretion of IL-17 and IL-22 after
in vitro stimulation with C. albicans as compared with
healthy (non-Candida-infected) donors. In concordance with
previous reports (Annunziato et al., 2007; LeibundGut-
Landmann et al., 2007; Singh et al., 2008), our data show
that the source of IL-17 in PBMCs is almost exclusively
limited to CD4þ CCR-6þ T cells. T-cell-receptor-specific
58.57 37.570.14 1.08
0.01 0.11
CCR6
104
104
103
103
102
102
101
101100
104
104
103
103
102
102
101
101100
IL-17
CMC
IC
35
30
25
20
15
10
5
0
%
 o
f T
 c
el
ls
CCR4+ CCR6+ CCR4+CCR6+
Figure 2. The CCR6þ IL-17Aþ cell population is strongly decreased in
CMC patients, while the total number of CCR4þCCR6þ cells is not
diminished. PBMCs of CMC patients and healthy controls were stained
intracellularly after phorbol 12-myristate 13-acetate/ionomycin stimulation
for IL-17 (a) (one representative experiment of three is shown) and analyzed
for expression of the surface markers CCR4 and CCR6 (b) by flow cytometry
(CMC patients, n¼ 3 and healthy controls, n¼ 4). Error bars indicate
mean±SD (IC, immunocompetent non-Candida-infected control).
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stimulation of PBMCs and stimulation of isolated CD4þ T
cells with autologous monocytes showed comparable
amounts of secreted IL-17, indicating that IL-17 was
predominantly derived from CD4þ T cells. Flow cytometry
analysis of PBMCs revealed nearly all cells positive
for IL-17 in intracellular staining to be positive also for
CCR-6.
However, even though they had been chronically exposed
to C. albicans, PBMCs from CMC patients secreted signifi-
cantly lower amounts of IL-17 and IL-22 than PBMCs from
healthy donors and patients with current Candida infection,
after stimulation with C. albicans in vitro—both on the mRNA
and on protein level. The underlying immune defect was not
specific for the Candida stimulus, as mitogen stimulation
(PHA) and T-cell-receptor-specific stimulation (anti-CD3/
anti-CD28) also resulted in reduced secretion of IL-17 and
IL-22 in CMC patients. This decrease was due to a strongly
diminished total number of IL-17 producing T cells, as
detected by surface CCR-6 and intracellular IL-17 staining
of PBMCs by flow cytometry. The weaker secretion of IL-22
was less pronounced than that of IL-17, as compared with
immunocompetent patients either infected or not infected
with Candida. This could be explained by the fact that IL-22
production is not limited to Th17 cells, but is also produced
by other activated T-cell subtypes (Xie et al., 2000; Conti
et al., 2003).
The so far identified differentiation factors for human
IL-17-producing T cells are IL-1b and IL-6 (Acosta-Rodriguez
et al., 2007a), whereas IL-23 seems to be important
for maintaining production of IL-17 and IL-22 in mouse
(Chen et al., 2006; Veldhoen et al., 2006; Kreymborg et al.,
2007), but to a lesser degree in human IL-17-producing
T cells (Acosta-Rodriguez et al., 2007a, b). In concordance
with these studies, we observed strong enhancement of IL-1b
and IL-6, but not of IL-23, after stimulation with Candida. The
secretion of these cytokines in PBMCs of patients suffering
from CMC was not diminished. In contrast, mRNA expression
of IL-1b and IL-6 was induced much stronger in CMC
patients, resulting in slightly higher release of proteins after
72 hours. This could indicate a defect in differentiation or
survival of IL-17-producing T cells downstream of IL-1b and
IL-6.
Concerning the mechanism of the candidicidal effects of
IL-17-producing T cells, two possible pathways could be
involved in clearing infection: on the one hand, there is the
strong neutrophil-recruiting capacity of IL-17 via induction of
IL-8 in human keratinocytes (Albanesi et al., 1999). On the
other hand, IL-17 and IL-22 synergistically induce b-defensins
in human keratinocytes (Liang et al., 2006) that are able to
kill C. albicans (Feng et al., 2005; Vylkova et al., 2007).
Taken together, a decrease in the absolute number of IL-17-
producing T cells and the resulting diminished stimulation
of epithelial cells could explain why candidiasis is limited to
the skin and mucosal membranes in CMC patients, and help
to understand why such patients do not suffer from systemic
candidiasis.
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Figure 3. No significant differences in Th17-differentiating cytokine secretion between CMC patients and healthy volunteers. Total mRNA was isolated from
Candida-stimulated PBMCs (CMC patients, n¼2; IC, non-Candida-infected control, n¼2) after 24 hours and analyzed for expression of IL-1b and IL-6 by real-
time PCR (a). The supernatants were analyzed after 72 hours by ELISA (CMC patients, n¼4; IC, non-Candida-infected control, n¼ 9; IC, Candida-infected
control, n¼ 6) (b). There were no significant differences in secretion of IL-1b and IL-6 between patients and controls. Error bars indicate mean±SD (IC,
immunocompetent control).
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In summary, this study underlines the importance of IL-17-
producing T cells for clearance of Candida infections.
Furthermore, our data suggest that an impaired IL-17 and
IL-22 response seems to be, at least in part, responsible for the
pathogenesis of CMC. With its limited number of CMC
patients, the power of this study is not high enough to draw
general conclusions. Therefore, further studies with greater
numbers of CMC patients will be required to investigate the
immune response of IL-17-producing T cells in order to
elucidate the pathomechanisms of CMC.
MATERIALS AND METHODS
Patients
Four CMC patients (three female, one male; age 8–50 years, mean
31 years; all suffering from chronic Candida infections of the skin
and esophagous since early childhood) were included into the study
and compared with nine healthy, age and sex-matched volunteers.
Furthermore, six patients suffering from an (at the time of investi-
gation) untreated Candida infection (two paronychia, two oral,
and two genital candidiasis) without any immune suppression were
enrolled into the study. Before drawing blood, each participant
provided informed consent. The study was approved by the ethical
committee of the Technical University Munich and followed the
Declaration of Helsinki Principles (41st World Medical Assembly,
1997).
Quantitative mRNA analysis
PBMCs of two CMC patients and two healthy volunteers were
stimulated with Candida antigen (100mgml1; Allergopharma,
Hamburg, Germany), PHA (10 mgml1), or anti-CD3/antiCD28
antibodies, respectively, for 6 hours. Total mRNA was extracted
using PeqGold RNA extraction buffer (Peqlab, Erlangen, Germany).
RNA was reverse transcribed using oligo(dT) primers and avian
myeloblastosis virus reverse transcriptase (Roche, Mannheim,
Germany). PCRs were performed with the following primers: IL-
17A (forward 50-CTCGATTTCACATGCCTTCA-30; reverse 50-GAGG
GGCCTTAATCTCCAAA-30), IL-17F (forward 50-AGTTGGAGAAGG
TGCTGGTG-30; reverse 50-CCATCCGTGCAGGTCTTATT-30), IL-22
(forward 50-GAGGAATGTGCAAAAGCTGA-30; reverse 50-GCTTT
GGGGCATCTAATTGT-30), IL-23A (forward 50-CAGTTCTGCTTG
CAAAGGAT-30; reverse 50-ATCTGCTGAGTCTCCCAGTG-30), IL-1b
(forward 50-TTCGACACATGGGATAACGA-30; reverse 50-TCTTTCA
ACACGCAGGACAG-30), and IL-6 (forward 50-ATGCAATAACCAC
CCCTGAC-30; reverse 50-GAGGTGCCCATGCTACATTT-30) (all from
www.realtimeprimers.com) and SYBR green mastermix (Bio-Rad,
Munich, Germany). PCRs were run on an ABI Prism 7000 Sequence
Detection System (Applied Biosystems, Foster City, CA) using the
following program: 10minutes at 94 1C followed by 45 cycles of
15 seconds at 95 1C and 60 seconds at 58 1C. 18S RNA served as the
housekeeping gene.
T-cell proliferation and cytokine secretion
PBMCs were separated as previously described (Eyerich et al., 2007)
and stimulated for 60hours either with 10mgml1 PHA as a positive
control or with 100mgml1 C. albicans antigen (Allergopharma). After
60hours, 100ml per well of supernatant was obtained and stored at
70 1C until further analysis by ELISA. Quantification of cytokines in
the supernatants was performed by ELISA, according to the
manufacturer’s instructions (IL-17, IL-22; R&D Systems, Wiesbaden,
Germany, and IL-1b, IL-6; BD Biosciences, Heidelberg, Germany).
Additionally, CD4þ and CD8þ T cells were isolated from
PBMCs of one CMC patient and a matched control, as previously
described, and stimulated with mitogen or Candida in the presence
of monocytes that served as antigen-presenting cells.
Intracellular cytokine staining
PBMCs from CMC patients and healthy controls were stimulated
with phorbol 12-myristate 13-acetate (20 ngml1) and ionomycin
(1 ngml1) (both from Sigma-Aldrich, Munich, Germany) for 6 hours
and examined for intracellular IL-17 accumulation.
To prevent cytokine secretion, the stimulation was performed in
the presence of Monensin (from the beginning) and brefeldin-A
(10 gml1; Sigma-Aldrich) was added for the final 4 hours. T cells
were fixed (2% paraformaldehyde), permeabilized (0.5% saponin),
and stained with phycoerythrin-conjugated anti-human IL-17
(eBioscience, San Diego, CA) antibody or isotype-matched control
antibody, and analyzed by flow cytometry.
Statistical analysis
Statistical analysis was performed with the software program
SPSS 14.0. All results were analyzed by Mann—Whitney U-test.
Statistically significant differences between CMC patients and
controls were defined as Po0.05.
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